SEARCH

SEARCH BY CITATION

References

  • 1
    Jemal A, Siegel R, Ward E, Murray T, Xu J, Smigal C, Thun MJ. Cancer statistics 2006. CA Cancer J Clin 2006; 56: 10630.
  • 2
    Ding XZ, Hennig R, Adrian TE. Lipoxygenase and cyclooxygenase metabolism: new insight in treatment and chemoprevention of pancreatic cancer. Mol Cancer 2003; 7: 210.
  • 3
    Funk CD. Prostaglandin and leukotrienes: advances in eicosanoid biology. Science 2001; 294: 18715.
  • 4
    Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton TS, Simmons DL. COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression. Proc Natl Acad Sci USA 2002; 99: 1392631.
  • 5
    Jones DA, Carlton DP, McIntyre TM, Zimmerman GA, Prescott SM. Molecular cloning of human prostaglandin endoperoxide synthase type II and demonstration of expression in response to cytokines. J Biol Chem 1993; 268: 904954.
  • 6
    Dubois RN, Awad J, Morrow J, Robert LJ,II, Bishop PR. Regulation of eicosanoid production and mitogenesis in rat intestinal epithelial cells by transforming growth factor-α and phorbol ester. J Clin Invest 1994; 93: 4938.
  • 7
    Hamasaki Y, Kitzler J, Hardman R, Nettesheim P, Eling TE. Phorbol ester and epidermal growth factor enhance the expression of two inducible prostaglandin H synthase genes in rat tracheal epithelial cells. Arch Biochem Biophys 1993; 304: 22634.
  • 8
    Li M, Wu X, Xu XC. Induction of apoptosis by cyclooxygenase-2 inhibitor NS398 through a cytochrome C dependent pathway in esophageal cancer cells. Int J Cancer 2001; 93: 21823.
  • 9
    Tsujii M, Dubois RN. Alteration in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell 1995; 83: 493501.
  • 10
    Gately S. The contribution of cyclooxygenase-2 to tumor angiogenesis. Cancer Metastasis Rev 2000; 19: 1927.
  • 11
    Fosslien E. Review: molecular pathology of cyclooxygenase-2 in cancer induced angiogenesis. Ann Clin Lab Sci 2001; 31: 32548.
  • 12
    Tsujii M, Kawano S, DuBois RN. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potiential. Proc Natl Acad Sci USA 1997; 94: 333640.
  • 13
    Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM, Soslow RA, Macferrer JL, Woerner BM, Koki AT, Fahey TJ,III. Cyclooxygenase-2 expression is upregulated in human pancreatic cancer. Cancer Res 1999; 59: 98790.
  • 14
    Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin A, Marshall SJ, Crowell PL, Marshall MS, Sweeney CJ. Cyclooxygenase-2 expression in human pancreatic adenocarcinomas. Carcinogenesis 2000; 21: 13946.
  • 15
    Merati K, said Saidaty M, Andea A, Sarkar F, Ben-Josef E, Mohammad R, Philip P, Shields AF, Vaitkevicius V, Grignon DJ, Adsay NV. Expression of inflammatory modulator COX-2 in pancreatic ductal adenocarcinoma and its relationship to pathologic and clinical parameters. Am J Clin Oncol 2001; 24: 44752.
  • 16
    El-Rayes BF, Ali S, Sarkar FH, Philip PA. Cyclooxygenase-2 dependent and independent effects of celecoxib in pancreatic cancer cell lines. Mol Cancer Ther 2004; 3: 142126.
  • 17
    Oshima M, Dinchuk JE, Kargman SL, Oshima H, Hancock B, Kwong E, Trzaskos JM, Evans JF, Taketo MM. Suppression of intestinal polyposis in Apc δ716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996; 87: 8039.
  • 18
    Chulada PC, Thompson MB, Mahler JF, Doyle CM, Gaul BW, Lee C, Tiano HF, Morham SG, Smithies O, Langenbach R. Genetic disruption of ptgs-1 as well as ptgs-2, reduces intestinal tumorigenesis in Min mice. Cancer Res 2000; 60: 47058.
  • 19
    Amir M, Agarwal HK. Role of COX-2 selective inhibitors for prevention and treatment of cancer. Pharmazie 2005; 60: 56370.
  • 20
    Liu NB, Peng T, Pan C, Yao YY, Shen B, Leng J. Overexpression of cyclooxygenase-2 in human HepG2, Bel-7402 and SMMC-7721 hepatoma cell lines and mechanism of cyclooxygenase-2 selective inhibitor celecoxib-induced cell growth inhibition and apoptosis. World J Gastroenterol 2005; 11: 62817.
  • 21
    Rice PL, Peters SL, Beard KS, Ahnen DJ. Sulindac independently modulates extracellular signal-regulated kinase [1/2] and cyclic GMP-dependent protein kinase signaling pathways. Mol Cancer Ther 2006; 5: 74654.
  • 22
    Aggarwal S, Taneja N, Lin L, Orringer MB, Rehmtulla A, Beer DG. Indomethacin induced apoptosis in esophageal adenocarcinoma cells involves upregulation of Bax and translocation of mitochondrial cytochrome C independent of COX-2 expression. Neoplasia 2000; 2: 34656.
  • 23
    Furberg CD, Psaty BM, Fitzgerald GA. Parecoxib, valdecoxib and cardiovascular risk. Circulation 2005; 111: 249.
  • 24
    Saha DK, Padhye S, Padhye S. Targeting estrogen receptor sites in human breast cancer cell line T47D with copper conjugates of non steroidal anti-inflammatory drug derivatives: antiproliferative activity of ketoprofen derivative and its copper complex. Metal based drugs 2001; 8: 737.
  • 25
    Padhye S, Afrasiabi Z, Sinn E, Fok J, Mehta K, Rath N. Antitumor metallothiosemicarbazonates: structure and antitumor activity of palladium complex of phenenthrenequinone thiosemicarbazone. Inorg Chem 2005; 44: 11546.
  • 26
    VLife Sciences technologies. MDS 2.0 Molecular Design Suite, VLife Sciences technologies Pvt Ltd, Pune, India, 2003.
  • 27
    Rowlinson SW, Kiefer JR, Prusakiewicz JJ, Pawlitz JL, Kozak KR, Kalgutkar AS, Stallings WC, Kurumbail RG, Marnett LJ. A novel mechanism of cyclooxygenase-2 inhibition involving interactions with Ser-530 and Tyr-385. J Biol Chem 2003; 278: 457639.
  • 28
    Chang G, Guida WC, Still WC. An internal coordinate monte carlo method for searching conformational space. J Am Chem Soc 1989; 111: 437986.
  • 29
    Halgren TA. Merck molecular force field. I. Basis, form, scope, parameterialization, and performance of MMFF94. J Comput Chem 1996; 17: 490519.
  • 30
    Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML, Sinicrope FA. Increased cyclooygenase-2 expression in human pancreatic carcinomas and cell lines: growth inhibition by nonsteroidal anti-inflammatory drugs. Cancer Res 1999; 59: 435662.
  • 31
    Peng JP, Liu LT, Chang HC, Hung WC. Enhancement of chemotherapeutic drug-induced apoptosis by a cyclooxygenase-2 inhibitor in hypopharyngeal carcinoma cells. Cancer Lett 2003; 201: 15763.
  • 32
    Sugiura T, Saikawa Y, Kubota T, Suganuma K, Otani Y, Watanabe M, Kumai K, Kitajima M. Combined chemotherapy with JTE-522 novel selective cyclooxygenase-2 inhibitor and cisplatin against gastric cancer cell lines in vitro and in vivo. In Vivo 2003; 17: 22933.
  • 33
    Uddin MJ, Rao PNP, Knaus EE. Design and synthesis of (Z)-1,2-diphenyl-1-(4-methanesulfonamidophenyl) alk-1-enes and (Z)-1-(4-azidophenyl)-1,2-diphenylalk-1-enes: novel inhibitors of cyclooxygenase-2 (COX-2) with anti-inflammatory and analgesic activity. Bioorg Med Chem 2005; 13: 41724.
  • 34
    Sheng H, Shao J, Kirkland SC, Isakson P, Coffey RJ, Morrow J, Beauchamp RD, DuBois RN. Inhibition of human colon cancer cell growth by selective inhibition of cyclooxygenase-2. J Clin Invest 1997; 99: 22549.
  • 35
    Meagher EA. Cardiovascular and renovascular implications of COX-2 inhibition. Curr Pharm Des 2004; 10: 60311.
  • 36
    DeMaria AN, Weir MR. Coxib-beyond the GI tract: renal and cardiovascular issues. J pain symptom manage 2003; 25: S41S49.
  • 37
    Ali S, El-Rayes BF, Sarkar FH, Philip PA. Simultaneous targeting of the epidermal growth factor receptor and cyclooxygenase-2 pathways for pancreatic cancer therapy. Mol Cancer Ther 2005; 4: 194351.
  • 38
    Li M, Lotan R, Levin B, Tahara E, Lippman SM, Xu XC. Aspirin induction of apoptosis in esophageal cancer; a potential for chemoprevention. Cancer Epidemiol Biomarkers Prev 2000; 9: 5459.
  • 39
    Israels LG, Israels ED. Apoptosis. Stem Cells 1999; 17: 3064.
  • 40
    Green DR, Reed JC. Mitochondria and apoptosis. Science 1998; 281: 130912.
  • 41
    Tsujimoto Y, Shimizu S. Bcl-2 family: life-or-death switch. FEBS Lett 2000; 466: 610.
  • 42
    Kroemer G, Reed JC. Mitochondrial control of cell death. Nat Med 2000; 6: 51319.